Loading stock data…
SABS
$3.47-0.27 (-7.22%)
Market ClosedLast close May 1
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SAB Biotherapeutics, Inc. in the Healthcare sector is trading at $3.47. The stock is currently 47% below its 52-week high of $6.60, remaining 5.8% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why SABS maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.47
Potential Upside
5%
Whystock Fair Value$3.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$280.40M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.76%
Volume
Today's trading volume
626,007
Recent News
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf
SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy in type 1 diabetes (T1D), emphasizing development of a fully human anti-thymocyte globulin (ATG) designed to preserve pancreatic beta cell function in newly d
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026
SAB Biotherapeutics (NASDAQ:SABS) used a presentation at Guggenheim’s Emerging Outlook Biotech Summit 2026 to outline its strategy in type 1 diabetes (T1D), focusing on a pivotal Phase 2b program for its lead candidate SAB-142. CEO Sam Reich said the company’s mission is to “transform what it means
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
While mega-cap tech stocks with trillion-dollar valuations tend to dominate market headlines, they aren’t the only games in town. Smaller companies, especially those at the low end of the price spectrum, can offer meaningful upside. These are the so-called penny stocks – traditionally associated with shares trading for just pennies, but today defined more broadly as stocks priced below $5. At these low price levels, even small absolute price increases can translate into outsized percentage gains
SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week
Key Insights SAB Biotherapeutics' significant individual investors ownership suggests that the key decisions are...
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.